Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors...
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13,...
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May...
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel...
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is...
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that...
Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized...
Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA FilingDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical...
Long-term clinical evaluation represents key advancement following successful first-in-human studyRUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq:...
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placeboFindings support progression...
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:...
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete...
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investorsInvestment accelerates advancement of RPT1G, a novel NAMPT...
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Atlanta-based firm to begin clinical trial on advanced warning seizure monitor ATLANTA, May 13, 2025 /PRNewswire/ -- KNoW Biological has...
GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among 600 registered teams from 58...
Electronic Health Systems Pioneer Carla Balch Joins Aranscia's Executive Leadership Team HOUSTON, May 12, 2025 /PRNewswire/ -- Aranscia, a global...
LAS VEGAS, May 12, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova...
Over 600 competing teams from 58 countries entered global competition. Teams with a broad range of potential solutions for healthspan...